News coverage about Immunomedics (NASDAQ:IMMU) has trended somewhat positive recently, Accern reports. Accern identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Immunomedics earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.7507298591267 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news articles that may have effected Accern’s analysis:
- Immunomedics, Inc. (IMMU) Given Consensus Rating of “Buy” by Analysts (americanbankingnews.com)
- Georgia Tech dismisses 2016 leading rusher Dedrick Mills, its best player (currenthollywood.com)
- Immunomedics Inc (IMMU) Buy, Hold or Sell? – ExpertGazette (expertgazette.com)
- Immunomedics, Inc. (IMMU) Internals Are Exhibiting Conflicting Signs – StockNewsGazette (stocknewsgazette.com)
- Valeant Pharmaceuticals Intl Inc’s Glaucoma Drug Could Be A Blockbuster, Immunomedics, Inc.’s Breast Cancer Drug … – Smarter Analyst (smarteranalyst.com)
Immunomedics (IMMU) traded up 5.51% during mid-day trading on Friday, hitting $8.42. 3,069,139 shares of the stock were exchanged. The company has a 50 day moving average price of $8.50 and a 200 day moving average price of $6.91. Immunomedics has a 52-week low of $2.02 and a 52-week high of $9.51. The firm’s market cap is $936.97 million.
Immunomedics (NASDAQ:IMMU) last announced its quarterly earnings data on Wednesday, August 16th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.13. The business had revenue of $0.64 million for the quarter, compared to the consensus estimate of $0.75 million. The business’s revenue for the quarter was down 31.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.17) earnings per share. On average, analysts anticipate that Immunomedics will post ($0.56) EPS for the current year.
A number of equities research analysts recently commented on the stock. Jefferies Group LLC reissued a “buy” rating and set a $11.00 target price on shares of Immunomedics in a research report on Friday, July 14th. Zacks Investment Research raised shares of Immunomedics from a “hold” rating to a “buy” rating and set a $10.00 target price for the company in a research report on Monday, July 17th. BidaskClub cut shares of Immunomedics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Cowen and Company reissued an “outperform” rating and set a $15.00 target price on shares of Immunomedics in a research report on Monday, July 24th. Finally, ValuEngine upgraded shares of Immunomedics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Immunomedics currently has an average rating of “Buy” and an average price target of $12.00.
ILLEGAL ACTIVITY WARNING: This story was posted by Rincon Hill News and is the sole property of of Rincon Hill News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://rinconhillneighbors.org/2017/08/19/immunomedics-nasdaqimmu-receives-daily-news-impact-rating-of-0-19-updated-updated.html.
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with our FREE daily email newsletter.